Leerink Partnrs Issues Negative Outlook for Geron Earnings

Geron Co. (NASDAQ:GERN) – Stock analysts at Leerink Partnrs lowered their Q4 2025 earnings per share estimates for Geron in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million.

A number of other research firms also recently weighed in on GERN. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price target for the stock from $3.50 to $2.00 in a research note on Thursday. Stifel Nicolaus dropped their price objective on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday. Scotiabank reduced their target price on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. Needham & Company LLC dropped their price target on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Finally, HC Wainwright downgraded Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.68.

Geron Trading Up 1.1 %

Shares of GERN stock opened at $1.76 on Thursday. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The firm’s 50-day simple moving average is $2.97 and its 200-day simple moving average is $3.80. The firm has a market cap of $1.06 billion, a P/E ratio of -5.50 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Institutional Trading of Geron

Several institutional investors and hedge funds have recently bought and sold shares of GERN. SBI Securities Co. Ltd. bought a new stake in shares of Geron in the 4th quarter valued at approximately $28,000. Integrated Wealth Concepts LLC acquired a new position in Geron in the fourth quarter worth $36,000. GF Fund Management CO. LTD. bought a new stake in Geron during the fourth quarter valued at $45,000. Fifth Lane Capital LP acquired a new stake in shares of Geron during the fourth quarter worth $53,000. Finally, Readystate Asset Management LP bought a new position in shares of Geron in the 3rd quarter worth about $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.